TSO3 — Investor Presentation (February 2016)
28 slides from TSO3's investor presentation, February 2016
Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing
TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation February 2016
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing
Slide 3: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) All Dollars in USD TSX:TOS Stock Price2 (2/15/16) US$1.26 Total Revenue (ttm) $1.2M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low2 $1.63 -$0.82 Net Income (ttm) $(5.1)M Avg. Daily Vol. (3 mo.) 291K • High-margin consumables and EPS (ttm) $(0.06) maintenance offer su
Slide 4: TSO3 - Who We Are
TSO3 - Who We Are TSX:TOS An industry Innovator in medical device sterilization FDA-cleared low temperature sterilization system with breakthroughs in capabilities, effectiveness and cost Global Distribution Partner Razor/Razorblade business model: proprietary consumables create high-margin re
Slide 5: Large Target Market
Large Target Market TSX:TOS Global Sterilization Equipment Market1 Global sterilization equipment market is expected grow ($ billions) at a 7.6% CAGR to $6.1 billion by 20201 Market segmented into equipment, consumables and $6.1B accessories, and contract sterilization services $5.7B $5.3B Con
Slide 6: Key Market Driver: Demographics
Key Market Driver: Demographics TSX:TOS Global population is aging Aging U.S. Population Expected to U.S. 65+ age group to grow 35%, from 40 million in 2010 to 54 million by 20201 Drive Growth in MIS Surgical Globally, 65+ to grow >100% by 20202 Services Patients age 65+ currently consume 50
Slide 7: MIS Device and Endoscope Use - Increasing the Need for Low-Temperature Sterilization
MIS Device and Endoscope Use - Increasing the Need for Low-Temperature Sterilization TSX:TOS 30 million+ Minimally Invasive Surgery (MIS) operations annually in U.S. and growing 700,000 ERCP procedures annually in the U.S.1 2 million colonoscopies annually in the U.S. 1 MIS benefits are driv
Slide 8: The Problem with Disinfection-only: Superbug & Endoscope Connection
The Problem with Disinfection-only: Superbug & Endoscope Connection TSX:TOS SUPERBUG = Antimicrobial Resistant Bacteria At least 2 million Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1 Half of all bugs that cause infections after surgery are antibiotic resistant2
Slide 9: Effective Medical Device Reprocessing is Critical to Reducing CRE Infections
Effective Medical Device Reprocessing is Critical to Reducing CRE Infections TSX:TOS Use of non-sterile devices contributes to increased Medical Reprocessing Lifecycle infection rates and hospital stays Therefore sterilization of reusable medical devices is an essential element for positive surg
Slide 10: Important Regulatory Growth Driver
Important Regulatory Growth Driver TSX:TOS FDA has recently identified flexible endoscopes as known source of infection and cause of death FDA has recorded 109 reports of infections or contamination related to bronchoscopes over the FDA safety communication: past five years, including 50 in 2014
Slide 11: Our Answer to these Issues and Challenges?
Our Answer to these Issues and Challenges? TSX:TOS The FDA-Cleared, STERIZONE® VP4 Sterilizer - Dual Sterilant, Low Temperature Sterilization System - Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, fewer Proprietary Software automatically operator errors due to error fre
Slide 12: STERIZONE VP4 Sterilizer Features
STERIZONE® VP4 Sterilizer Features TSX:TOS Broadest global regulatory claims of any sterilizer Only FDA-cleared sterilizer utilizing dual sterilants (Hydrogen Peroxide and Ozone) Only new generation sterilizer with validated claims for colonoscopes, gastroscopes, and duodenoscopes (Canada and
Slide 13: Competitive Landscape
Competitive Landscape TSX:TOS Ethelyne Oxide Hydrogen Peroxide Hydrogen Peroxide Hydrogen Peroxide + Ozone Technology (ETO) (H2O2) (H2O2) (H2O2/O3) Cycle Mass n/a Up to 21 lb Up to 25 lb Up to 75 lb Cycle Times 18-23 hours 21-56 mins 24-60 mins 46 mins Device moderate Low Low High Processing Flexibi
Slide 14: Extensive Global Patent Portfolio Creates Competitive Barriers
Extensive Global Patent Portfolio Creates Competitive Barriers TSX:TOS Broad global patent coverage Our Global Patent Portfolio TSO3 sterilization method; selective Projected1 Submitted Granted control of condensation Use of its Dynamic Sterilant Delivery U.S. 1 8 6 System™ using the two steri
Slide 15: Partnering with Getinge for Global Sales and Service
Our Go-to-Market Strategy: Partnering with Getinge for Global Sales and Service TSX:TOS Getinge Global Presence USA Czech Getinge Infection Control (part of Getinge Group) Canada Republic Turkey Top global provider of infection control devices UK Associates: 3,089 China France
Slide 16: Exclusive Global Distribution Agreement
TSO3 and Getinge Exclusive Global Distribution Agreement TSX:TOS Q4 2015 - Getinge granted exclusive global distributor rights to STERIZONE® VP4 Sterilizer “The STERIZONE® VP4 Sterilizer uniquely addresses an unmet global US$7.5M license fee paid to TSO3 in Q4 2015 need for cost effective, high
Slide 17: Getinge Sales Target for TSO3 STERIZONE VP4 Sterilizer
Getinge Sales Target for TSO3 STERIZONE® VP4 Sterilizer TSX:TOS Getinge’s commitment: • Reflects unit deployments only 300+ >10% of the ~3,000 unit/US$450 million units1 • Higher-margin consumables annual global replacement market within and accessories are additional five years = 300+ units/yea
Slide 18: Recent Financials and Outlook
Recent Financials and Outlook All Dollars in USD TSX:TOS Total Revenue (ttm) $1.2M 2015 Quarterly Revenue Growth Annual Revenue Net Income (ttm) $(5.1)M ($ Millions) Revenue Growth EPS (ttm)¹ $(0.06) $0.90 ($ Millions) Cash & Short-term Investments2,3 $23.7M M Monthly Burn Rate ~$700K Total Assets (
Slide 19: Growth Strategies
Growth Strategies TSX:TOS Support Getinge for global introduction and commercialization of STERIZONE® VP4 Sterilizer Broaden product portfolio with development and commercialization of new products: Purpose-built or sterilizer products Iterations of existing systems for local market adoption
Slide 20: TSO3 Key Takeaways
TSO3 Key Takeaways TSX:TOS STERIZONE® VP4 Sterilizer: FDA-cleared medical device sterilization system with multiple breakthroughs in design, capability, effectiveness and operational cost Exclusive, performance-based global distribution agreement with Getinge: minimum sales commitment affirms ma
Slide 21: Contact Us
Contact Us TSX:TOS TSO3 Inc. - Canada Investor Relations 2505, avenue Dalton Québec, Québec Liolios Group, Inc. G1P 3S5 CANADA Ron Both, Senior Managing Director Tel (949) 574-3860 Tel (418) 651-0003 TOS@liolios.com info@tso3.com Renmark Financial Communications Inc. TSO3 Corporation - USA Barry Mir
Slide 22: Appendix
Appendix +,
Slide 23: Evolution of TSO3 - From Development Stage to Major Commercial Rollout
Evolution of TSO3 – From Development Stage to Major Commercial Rollout TSX:TOS 2000 2009 2010 2015 2015 2015 2015 125L Ozone Sterilizer Health Canada Received CE Mark Completed Additional Established Allowed received regulatory licenses notice of conformity CN$11.5 million patent first U.S. expanded
Slide 24: Senior Leadership
Senior Leadership TSX:TOS Richard Rumble, President and CEO Glen Kayll, Chief Financial Officer • President, CEO and director of TSO3 since October 2008 • Appointed CFO December 2015 • 25 years of experience in N. American and global medical device • Brings 20+ years of senior management experience,
Slide 25: Board of Directors
Board of Directors TSX:TOS Richard Rumble | Director Germain Carriere | Chairman • Chairman since June 1998. • In recent years, after holding the position of Vice Chairman, Corporate Strategy, at National Bank Financial Inc., he held the positions of President and Chief Operating Officer at Desjardi
Slide 26: Board of Directors (Cont'd)
Board of Directors (Cont’d) TSX:TOS Claude Michaud | Director • Joined TSO3 board in March 2013. • Brings to the board his expertise in corporate finance, mergers and acquisitions and corporate development. • Experienced finance executive and investment banker. 15-year career in investment banking w
Slide 27: FDA Links Superbug to Key Medical Device
FDA Links Superbug to Key Medical Device TSX:TOS FDA links "superbug" to key medical device On Thursday, the U.S. Food and Drug Administration issued an advisory warning doctors that even when a manufacturer's cleaning instructions are followed, infectious germs may linger in the devices. Advisory:
Slide 28: Evolution of Classification of Reprocessing Requirements
Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements TSX:TOS Since multi-channeled flexible Body Reprocessing FDA Device Class endoscopes, including Highest Contact Requirements Today Signaled colonoscopes and duodenoscopes are typically Sterile Body